![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NEUROPHARMACOLOGY
Neural Plasticity Research Group, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (F.A., L.B., H.W., T.A.S., C.J.W.); Pfizer Global Research and Development, Discovery Biology Research, Aichi, Japan (J.T.); and Department of Anesthesiology, Chang Gung Memorial Hospital, Kaohsiung Medical Center, Chung Gang University, Taiwan, Republic of China (C.-R.L.)
Prostaglandin E2 (PGE2) is both an inflammatory mediator released at the site of tissue inflammation and a neuromodulator that alters neuronal excitability and synaptic processing. The effects of PGE2 are mediated by four G-protein-coupled EP receptors (EP1-EP4). Here we show that the EP4 receptor subtype is expressed by a subset of primary sensory dorsal root ganglion (DRG) neurons, and that its levels, but not that of the other EP13 subtypes, increase in the DRG after complete Freund' adjuvant-induced peripheral inflammation. Administration of both an EP4 antagonist [AH23848, (4Z)-7-[(rel-1S,2S,5R)-5-((1,1'-biphenyl-4-yl)methoxy)-2-(4-morpholinyl)-3-oxocyclopentyl]-4-heptenoic acid] and EP4 knockdown with intrathecally delivered short hairpin RNA attenuates inflammation-induced thermal and mechanical behavioral hypersensitivity, without changing basal pain sensitivity. AH23848 also reduces the PGE2-mediated sensitization of capsaicin-evoked currents in DRG neurons in vitro. These data suggest that EP4 is a potential target for the pharmacological treatment of inflammatory pain.
Address correspondence to: Dr. Clifford J. Woolf, Neural Plasticity Research Group, Department of Anesthesia and Critical Care, Massachusetts General Hospital, 149 13th Street, Room 4309, Charlestown, MA 02129. E-mail: cjwoolf{at}partners.org
This article has been cited by other articles:
![]() |
Y.-J. Lai, S. S. Pullamsetti, E. Dony, N. Weissmann, G. Butrous, G.-A. Banat, H. A. Ghofrani, W. Seeger, F. Grimminger, and R. T. Schermuly Role of the Prostanoid EP4 Receptor in Iloprost-mediated Vasodilatation in Pulmonary Hypertension Am. J. Respir. Crit. Care Med., July 15, 2008; 178(2): 188 - 196. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Schnizler, L. P. Shutov, M. J. Van Kanegan, M. A. Merrill, B. Nichols, G. S. McKnight, S. Strack, J. W. Hell, and Y. M. Usachev Protein Kinase A Anchoring via AKAP150 Is Essential for TRPV1 Modulation by Forskolin and Prostaglandin E2 in Mouse Sensory Neurons J. Neurosci., May 7, 2008; 28(19): 4904 - 4917. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Clark, S. E. Rowland, D. Denis, M.-C. Mathieu, R. Stocco, H. Poirier, J. Burch, Y. Han, L. Audoly, A. G. Therien, et al. MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a Selective E Prostanoid Receptor 4 Antagonist, Relieves Joint Inflammation and Pain in Rodent Models of Rheumatoid and Osteoarthritis J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 425 - 434. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.M. Patwardhan, J. Vela, J. Farugia, K. Vela, and K.M. Hargreaves Trigeminal Nociceptors Express Prostaglandin Receptors Journal of Dental Research, March 1, 2008; 87(3): 262 - 266. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Takeuchi, A. Tanaka, S. Kato, E. Aihara, and K. Amagase Effect of (S)-4-(1-(5-Chloro-2-(4-fluorophenyoxy)benzamido)ethyl) Benzoic Acid (CJ-42794), a Selective Antagonist of Prostaglandin E Receptor Subtype 4, on Ulcerogenic and Healing Responses in Rat Gastrointestinal Mucosa J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 903 - 912. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Nakao, A. Murase, H. Ohshiro, T. Okumura, K. Taniguchi, Y. Murata, M. Masuda, T. Kato, Y. Okumura, and J. Takada CJ-023,423, a Novel, Potent and Selective Prostaglandin EP4 Receptor Antagonist with Antihyperalgesic Properties J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 686 - 694. [Abstract] [Full Text] [PDF] |
||||